Diagnostic Efficacy and Therapeutic Decision-making Capacity of an Artificial Intelligence Platform for Childhood Cataracts in Eye Clinics: A Multicentre Randomized Controlled Trial

Background CC-Cruiser is an artificial intelligence (AI) platform developed for diagnosing childhood cataracts and providing risk stratification and treatment recommendations. The high accuracy of CC-Cruiser was previously validated using specific datasets. The objective of this study was to compare the diagnostic efficacy and treatment decision-making capacity between CC-Cruiser and ophthalmologists in real-world clinical settings. Methods This multicentre randomized controlled trial was performed in five ophthalmic clinics in different areas across China. Pediatric patients (aged ≤ 14 years) without a definitive diagnosis of cataracts or history of previous eye surgery were randomized (1:1) to receive a diagnosis and treatment recommendation from either CC-Cruiser or senior consultants (with over 5 years of clinical experience in pediatric ophthalmology). The experts who provided a gold standard diagnosis, and the investigators who performed slit-lamp photography and data analysis were blinded to the group assignments. The primary outcome was the diagnostic performance for childhood cataracts with reference to cataract experts' standards. The secondary outcomes included the evaluation of disease severity and treatment determination, the time required for the diagnosis, and patient satisfaction, which was determined by the mean rating. This trial is registered with ClinicalTrials.gov (NCT03240848). Findings Between August 9, 2017 and May 25, 2018, 350 participants (700 eyes) were randomly assigned for diagnosis by CC-Cruiser (350 eyes) or senior consultants (350 eyes). The accuracies of cataract diagnosis and treatment determination were 87.4% and 70.8%, respectively, for CC-Cruiser, which were significantly lower than 99.1% and 96.7%, respectively, for senior consultants (p < 0.001, OR = 0.06 [95% CI 0.02 to 0.19]; and p < 0.001, OR = 0.08 [95% CI 0.03 to 0.25], respectively). The mean time for receiving a diagnosis from CC-Cruiser was 2.79 min, which was significantly less than 8.53 min for senior consultants (p < 0.001, mean difference 5.74 [95% CI 5.43 to 6.05]). The patients were satisfied with the overall medical service quality provided by CC-Cruiser, typically with its time-saving feature in cataract diagnosis. Interpretation CC-Cruiser exhibited less accurate performance comparing to senior consultants in diagnosing childhood cataracts and making treatment decisions. However, the medical service provided by CC-Cruiser was less time-consuming and achieved a high level of patient satisfaction. CC-Cruiser has the capacity to assist human doctors in clinical practice in its current state. Funding National Key R&D Program of China (2018YFC0116500) and the Key Research Plan for the National Natural Science Foundation of China in Cultivation Project (91846109).

[1]  Liming Wang,et al.  An artificial intelligence platform for the multihospital collaborative management of congenital cataracts , 2017, Nature Biomedical Engineering.

[2]  E. Finkelstein,et al.  Development and Validation of a Deep Learning System for Diabetic Retinopathy and Related Eye Diseases Using Retinal Images From Multiethnic Populations With Diabetes , 2017, JAMA.

[3]  S. Hashmi ‘Coming of Age’ of artificial intelligence: evolution of survivorship care through information technology , 2016, Bone Marrow Transplantation.

[4]  N. Congdon,et al.  Who will be wielding the lancet for China's patients in the future? , 2016, The Lancet.

[5]  Peter Szolovits,et al.  The coming of age of artificial intelligence in medicine , 2009, Artif. Intell. Medicine.

[6]  Sebastian Thrun,et al.  Dermatologist-level classification of skin cancer with deep neural networks , 2017, Nature.

[7]  Daniel S. Kermany,et al.  Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning , 2018, Cell.

[8]  Giuseppe Remuzzi,et al.  Rare diseases: what's next? , 2008, The Lancet.

[9]  Anagha Medsinge,et al.  Pediatric cataract: challenges and future directions , 2015, Clinical ophthalmology.

[10]  M. Dougados,et al.  An e-health interactive self-assessment website (Sanoia®) in rheumatoid arthritis. A 12-month randomized controlled trial in 320 patients. , 2017, Joint, bone, spine : revue du rhumatisme.

[11]  E H Shortliffe,et al.  Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  I. MacDonald,et al.  Extraocular muscle hypertrophy in myotonia congenita: Mutation identified in the SCN4A gene (V445M). , 2009, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[13]  Domenica Taruscio,et al.  National plans and strategies on rare diseases in Europe. , 2010, Advances in experimental medicine and biology.

[14]  Manoj Raju,et al.  Development of a Deep Learning Algorithm for Automatic Diagnosis of Diabetic Retinopathy , 2017, MedInfo.

[15]  Kelly Milne,et al.  Telemedicine in a Rural Memory Disorder Clinic—Remote Management of Patients with Dementia , 2012, Canadian geriatrics journal : CGJ.

[16]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[17]  Michael V. McConnell,et al.  Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning , 2017, Nature Biomedical Engineering.

[18]  F. Fregni,et al.  Sample size calculation in physical medicine and rehabilitation: a systematic review of reporting, characteristics, and results in randomized controlled trials. , 2011, Archives of physical medicine and rehabilitation.

[19]  Patrick Blake,et al.  Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine , 2015, Journal of Clinical Bioinformatics.

[20]  Arrigo Schieppati,et al.  Why rare diseases are an important medical and social issue , 2008, The Lancet.

[21]  Subhashini Venugopalan,et al.  Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. , 2016, JAMA.

[22]  Irwin Kleinman,et al.  A new law for allocation of donor organs in Israel , 2010, The Lancet.

[23]  Yi-Xiang J. Wang On the training of young doctors in China. , 2015, Quantitative Imaging in Medicine and Surgery.

[24]  Neil J. Joshi,et al.  Automated Grading of Age-Related Macular Degeneration From Color Fundus Images Using Deep Convolutional Neural Networks , 2017, JAMA ophthalmology.

[25]  P. Hamet,et al.  Artificial intelligence in medicine. , 2017, Metabolism: Clinical and Experimental.

[26]  Catherine Egan,et al.  Automated Diabetic Retinopathy Image Assessment Software: Diagnostic Accuracy and Cost-Effectiveness Compared with Human Graders. , 2016, Ophthalmology.

[27]  Johan Gustav Bellika,et al.  Standards for reporting randomized controlled trials in medical informatics: a systematic review of CONSORT adherence in RCTs on clinical decision support , 2011, J. Am. Medical Informatics Assoc..

[28]  C. Printz Artificial intelligence platform for oncology could assist in treatment decisions , 2017, Cancer.

[29]  P. Bacchetti,et al.  Sample size calculations in clinical research. , 2002, Anesthesiology.

[30]  Ji Hoon Kim,et al.  The Settings, Pros and Cons of the New Surgical Robot da Vinci Xi System for Transoral Robotic Surgery (TORS): A Comparison With the Popular da Vinci Si System , 2016, Surgical laparoscopy, endoscopy & percutaneous techniques.

[31]  M. Rodger,et al.  Diagnostic randomized controlled trials: the final frontier , 2012, Trials.

[32]  Richard Bowman,et al.  Global challenges in the management of congenital cataract: proceedings of the 4th International Congenital Cataract Symposium held on March 7, 2014, New York, New York. , 2015, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[33]  A. Curioni-Fontecedro,et al.  A new era of oncology through artificial intelligence , 2017, ESMO Open.